Amgen Inc., of Thousand Oaks, Calif., and Dublin-based Allergan plc, reported data from a phase III trial testing ABP-980, a Herceptin (trastuzumab, Roche Holding AG) biosimilar compared to the originator product in patients with human epidermal growth factor receptor 2-positive early breast cancer.